Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death

To evaluate the effectiveness of amiodarone as primary or secondary prevention in sudden cardiac death (SCD) compared with placebo or any other antiarrythmics in patients with high risk for sudden cardiac death, or who have recovered from a cardiac arrest or a syncope due to VT/VF. We aim to conduct a subgroup analysis for patients with or without ICD.